drugset / Trial / NCT02456935

Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis

NCT02456935

Phase 3 Completed 280 enrolled HK inno.N Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to demonstrate the efficacy of CJ-12420, once daily (QD), compared to esomeprazole in patients with erosive esophagitis classified as Los Angeles (LA) classification grades A to D at Week 8

Timeline

Start
2015-05
Primary completion
2016-07
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Esomeprazole Small molecule 40 mg Oral
Subject Tegoprazan Other / unclassified 100 mg Oral

Indications